Aktienanalyse zu Stryker Corp (SYK)SYKStryker Corp

Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Stryker Corp is currently a hold. The stock is priced at $330.69, with a forward P/E ratio of 21.88, which suggests it may be fairly valued for long-term growth. However, the RSI is at 49.47, indicating a neutral momentum, and hedge funds have increased selling by 119.77%, which raises concerns about market sentiment. The main risk is the ongoing supply chain disruptions impacting growth, as highlighted in recent earnings reports.

27 analysts cover SYK: 17 rate it Buy, 8 Hold and 2 Sell. The average price target is 430.32.